# Support of Collaborations with the ETCTN through the EDDOP

> **NIH NIH P30** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2020 · $67,470

## Abstract

Project Summary/Abstract
This application is being submitted in response to the NOSI identified as NOT-CA-20-017, “Administrative
Supplement to CCSG’s to Support Collaborations with the Experimental Therapeutics Clinical Trails Network
(ETCTN) through the Early Drug Development Opportunity Program (EDDOP).” The Rogel Cancer Center first
received National Cancer Institute (NCI) Cancer Center designation in 1988, and it has been a comprehensive
cancer center continuously since 1991. The Rogel Cancer Center has a long, successful track record of
participation in National Group clinical trial networks, including the National Clinical Trials Network (NCTN), the
Pediatric Early Phase Clinical Trials Network (PEP-CTN), and the Bone Marrow Transplant Clinical Trials
Network (BMT-CTN). The University of Michigan is a Lead Academic Participating Site (LAPS) in the NCTN,
supporting a core staff with specialized expertise in National Group trial registrations. Although previously a
part of the University of Chicago Phase II Consortium until 2016, we are not currently either a Lead Academic
Organization (LAO) or and Affiliated Organization (AO) for the ETCTN. In 2017, we were awarded a P30
supplement to participate in the Experimental Therapeutics Clinical Trials Network (ETCTN) as an Early Drug
Development Opportunity Program (EDDOP) site. This supplement supported Rogel Cancer Center activation
of one ETCTN trial in 2017 (A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with
Unresectable or Metastatic Epithelioid Hemangioendothelioma); which was led by a University of Michigan
investigator (Schuetze). We enrolled five patients on this trial from 2017-2019, when it reached its accrual goal.
In addition, in 2018 we activated an additional three ETCTN/EDDOP clinical trials, and we have enrolled six
patients on these trials to date. The Rogel Cancer center is committed to contributing to high priority early
phase trials through the ETCTN. Given our center’s history, and our faculty’s continued strong interest in
ETCTN trials, we will be able to meet or exceed the goal of five patients per year to support our continued
participation in the EDDOP program.

## Key facts

- **NIH application ID:** 10142573
- **Project number:** 3P30CA046592-31S3
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** Eric R. Fearon
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $67,470
- **Award type:** 3
- **Project period:** 1997-06-01 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10142573

## Citation

> US National Institutes of Health, RePORTER application 10142573, Support of Collaborations with the ETCTN through the EDDOP (3P30CA046592-31S3). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10142573. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*